FDA clears single-dose injectable formulation of Merck's EMEND for prevention of chemo-induced nausea and vomiting

• The FDA approves Merck's (NYSE:MRK -1.9%) supplemental New Drug Application (sNDA) for single-dose EMEND (fosaprepitant dimeglumine) for injection, in combination with other antiemetic medicines, for the prevention of delayed nausea and vomiting in adults receiving moderately emetogenic chemotherapy. It is the first intravenous single-dose NK1 receptor antagonist approved in the U.S.
• A one-to-three-day IV formulation was cleared in February 2008.